World Journal of Surgery

, Volume 31, Issue 6, pp 1180–1186 | Cite as

Role of Centchroman in Regression of Mastalgia and Fibroadenoma

Article

Abstract

Objectives

Centchroman (Ormeloxifene) is a novel non-steroidal, selective antiestrogen. Because of its selective antiestrogen action, centchroman has been used for treatment of mastalgia and fibroadenoma.

Materials and Methods

Benign breast disease patients up to 35 years of age attending our surgery outpatient department from August 2003 to September 2004 and fulfilling the inclusion criterion were included in this study. They were started on centchroman 30 mg on alternate days for a period of 3 months and were followed up for 6 months. Results were recorded as per clinical examination, visual analog scale (VAS) for pain, and ultrasonography for breast lump size.

Results

A total of 60 patients were included in this pilot study, 42 (70%) of whom had mastalgia with or without nodularity, and 18 (30%) had fibroadenoma. Noncyclical pain was recorded in 38 patients (90%), and cyclical pain was recorded in only 4 (10%) patients. A VAS score of 10 was recorded by 33 (80%) patients (severe pain), and the remaining 9 patients (20%) had VAS scores from 7 to 10. Fibroadenoma size ranged from 1.5 to 5 cm., single or multiple in one or both breasts. There was a good response in the mastalgia group, with a decrease in the VAS scoring from 10 to 3 in 90 % of the patients in the first week. Almost all of the patients were painless at the end of one month, with complete disappearance of the nodularity. In the fibroadenoma group there was a mixed response, with complete disappearence in 40%, partial regression in 20%, and no response at all in the remaining 40%. There were very few side effects.

Conclusions

Centchroman is a safe nonsteroidal drug for the treatment of mastalgia and fibroadenoma. It has shown good results in mastalgia and is a safe drug as compared to the drugs of choice used at present (danazole and bromocriptine). Further randomized studies are in progress and are needed to determine its definitive role in this patient group.

References

  1. 1.
    Goyal A, Mansel RE, on behalf of the Efamast study Group (2005) A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J 11:41–47PubMedCrossRefGoogle Scholar
  2. 2.
    Roberts MM, Elton RA, Robinson SE, et al. (1987) Consultations for breast disease in general practice and hospital referral patterns. Br J Surg 74:1020–1022PubMedCrossRefGoogle Scholar
  3. 3.
    Hughes LE, Mansel RE, Webster DJT (2000) Breast pain nodularity. In Hughes LE, Mansell RE, Webster DJT, editors, Benign Disorders and Diseases of the Breast: Concepts and Clinical Management, 2nd Edition, London, W. B. Saunders Company, 95–121Google Scholar
  4. 4.
    Fentiman IS, Caleffi M, Hamed H, et al. (1988) Dosage and duration of tamoxifen for mastalgia. A controlled trial. Br J Surg 75:845–846PubMedCrossRefGoogle Scholar
  5. 5.
    Preece PE, Richards AR, Owen GM, et al. (1975) Mastalgia and total body water. BMJ iv:498–500Google Scholar
  6. 6.
    Sitruk-Ware R, Sterkers N, Mauvais-Jarvis P (1979) Benign breast disease. 1: Hormonal investigation. Obstet Gynecol 53:457–460PubMedGoogle Scholar
  7. 7.
    Swain MC, Hayward JL, Bulbrool RD (1973) Plasma oestradiol and progesterone in benign breast disease. Eur J Cancer 9:553–556PubMedGoogle Scholar
  8. 8.
    England PC, Skinner LG, Cottrell IM, et al. (1974) Serum oestradiol-17 beta in women with benign and malignant breast disease. Br J Cancer 30:571–576PubMedGoogle Scholar
  9. 9.
    Malarkey WB, Schroeder LL, Stevens VC, et al. (1977) Twenty four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res 37:4655–4659PubMedGoogle Scholar
  10. 10.
    Cole EN, Sellwood RA, England PC, et al. (1977) Serum prolactin concentration on benign breast disease throughout the menstrual cycle. Eur J Cancer 13:597–603PubMedGoogle Scholar
  11. 11.
    Peters F, Pickardt CR, Zimmerman G, et al. (1981) PRL, TSH and thyroid hormones in benign breast disease. Klin Wochenschr 59:403–407PubMedCrossRefGoogle Scholar
  12. 12.
    Kumar S, Mansel RE, Hughes LE, et al. (1984) Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53:1311–1315PubMedCrossRefGoogle Scholar
  13. 13.
    Khanna AK, Tapodar JK, Khanna HD, et al. (2002) Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders. Eur J Surg 168:631–634PubMedCrossRefGoogle Scholar
  14. 14.
    Horrobin DF, Manku MS (1989) Premenstrual syndrome and premenstrual breast pain: disorders of essential fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 37:255–261PubMedCrossRefGoogle Scholar
  15. 15.
    Gateley CA, Maddox PR, Pritchard GA, et al. (1992) Plasma fatty acid profiles in benign breast disorders. Br J Surg 79:407–409PubMedCrossRefGoogle Scholar
  16. 16.
    Sharma AK, Mishra SK, Salia M, et al. (1994) Cyclical mastalgia—is it a manifestation of aberration in lipid metabolism? Indian J Physiol Pharmacol 38:267–271PubMedGoogle Scholar
  17. 17.
    Barros AC, Mottola J, Ruiz CA, et al. (1999) Reassurance in the treatment of mastalgia. Breast J 5:162–165PubMedCrossRefGoogle Scholar
  18. 18.
    Hadi MS (2000) Sports brassiere: is it a solution for mastalgia? Breast J 6:407–409PubMedCrossRefGoogle Scholar
  19. 19.
    Boyd NF, Maguire V, Shannon P, et al. (1989) A clinical trial of low fat high carbohydrate diet in patients with cyclical mastalgia. Breast Cancer Res Treat 10:117Google Scholar
  20. 20.
    Ernster VL, Mason L, Goodson WH, et al. (1982) Effects of caffeine free diet on benign breast disease: a randomised trial. Surgery 91:263–267PubMedGoogle Scholar
  21. 21.
    Minton JP, Foeking MK, Webster DJT, et al. (1979) Response of fibrocystic disease to caffeine withdrawal and correlation with cyclic nucleotides with breast disease. Am J Obstet Gynecol 135:157PubMedGoogle Scholar
  22. 22.
    Ory H, Cole P, MacMahon B (1976) Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 294:419–422PubMedCrossRefGoogle Scholar
  23. 23.
    Colak T, Ipek T, Kanik A, et al. (2003) Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J Am Coll Surg 196:525–530PubMedCrossRefGoogle Scholar
  24. 24.
    Pashby NL, Mansel RE, Hughes LE, et al. (1981) A clinical trial of evening primrose oil in mastalgia. Br J Surg 68:801CrossRefGoogle Scholar
  25. 25.
    Blommers J, de Lange-De Klerk ES, Kuik DJ, et al. (2002) Evening primrose oil and fish oil for severe chronic astalgia: a randomized, double-blind, controlled trial. Am J Obstet Gynecol 187:1389–1394PubMedCrossRefGoogle Scholar
  26. 26.
    Goyal A, Mansel RE, on behalf of the Efamast study Group (2005) A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J 11:41–47PubMedCrossRefGoogle Scholar
  27. 27.
    Greenblatt RB, Dmowske WP, Mhesh VB, et al. (1971) Clinical studies with an antigonadotrophin-Danazol. Fertil Steril 22:102–112PubMedGoogle Scholar
  28. 28.
    Asch RH, Greenblatt RB (1971) The use of an impeded androgen Danazol in the management of benign breast disorders. Am J Obstet Gynecol 127:130–134Google Scholar
  29. 29.
    Mansel RE, Wisbey JR, Hughes LE (1982) Controlled trial of the antigonadotrophin danazol in painful nodular benign breast disease. Lancet 928–931Google Scholar
  30. 30.
    Harrison BJ, Maddox PR, Hughes LE (1989) Maitenance therapy of cyclical mastalgia using low dose Danazol. J R Coll Surg Edinb 34:79–84PubMedGoogle Scholar
  31. 31.
    Hinton CP, Bishop HM, Holliday HW, et al. (1986) A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. Br J Clin Pract 40:326–330PubMedGoogle Scholar
  32. 32.
    Mansel RE, Preece PE, Hughes LE (1978) A double-blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Br J Surg 65:724–727PubMedCrossRefGoogle Scholar
  33. 33.
    Blichert-Tolt M, Anderson AN, Henriksen OB, et al. (1979) Treatment of mastalgia with bromocriptine. A double blind crossover study. BMJ 1:237CrossRefGoogle Scholar
  34. 34.
    Durning P, Sellwood RA (1982) Bromocriptine in severe cyclical breast pain. Br J Surg 69:248–249PubMedCrossRefGoogle Scholar
  35. 35.
    Mansel RE, Dogliotti L (1990) European multicentre trial of bromocriptine in cyclical mastalgia. Lancet 335:190–193PubMedCrossRefGoogle Scholar
  36. 36.
    Mansel RE (1981) A review of the role of bromocriptine in symptomatic benign breast disease. Res Clin Forum 3:61–63Google Scholar
  37. 37.
    Fentiman IS, Caleffi M, Brame K, et al. (1986) Double-blind controlled trial of tamoxifen therapy for mastalgia. Lancet 8376:287–288CrossRefGoogle Scholar
  38. 38.
    Mansal E, Goyal A, Preece P, et al. (2004) European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. Am J Obstet Gynecol 191:1942–1949CrossRefGoogle Scholar
  39. 39.
    Lawrence WB, Valerie PJ (1997) Diagnosis of Diseases of the Breast, 1st Edition, Philadelphia, W. B. Saunders Company, 385Google Scholar
  40. 40.
    Dent DM, Cant PJ (1989) Fibroadenoma. World J Surg 13:706–710PubMedCrossRefGoogle Scholar
  41. 41.
    Vivani RS, Gebrim LH, Baracat EC, De Lima GR (2002) Evaluation of the ultrasonographic volume of breast fibroadenomas in women treated with tamoxifen. Minerva Gynecol 54:531–535Google Scholar
  42. 42.
    Kamboj VP, Ray S, Dhawan BN (1992) Centchroman. Drugs Today 28:227–232Google Scholar
  43. 43.
    Kamboj VP, Kar AB, Ray S, Grover PK, Anand N (1971) Antifertility activity of 3,4-trans-2,2-dimethyl-3-phenyl-4-p(β-pyrrolidinoethoxy)-phenyl-7 methoxychroman. Indian J Exp Biol 9:103–104Google Scholar
  44. 44.
    Kamboj VP, Sing MM, Kar AB (1973) Effect of some non-steroidal antifertility agents on the biochemistry of the uterus and uterine fluids in rats. Indian J Exp Biol 11:479–483PubMedGoogle Scholar
  45. 45.
    Kamboj VP, Setty BS, Chandra H, Roy SK, Kar AB (1977) Biological profile of centchroman——A new post-coital contraceptive. Indian J Exp Biol 15:1144–1150PubMedGoogle Scholar
  46. 46.
    Datta JK, Roy S (1977) Effect of centchroman on morphological and biochemical changes induced by testosterone propionate in uterus of rats. Indian J Exp Biol 15:1157–1158Google Scholar

Copyright information

© Société Internationale de Chirurgie 2007

Authors and Affiliations

  1. 1.Department of SurgeryAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations